title: Treatment of infantile haemangiomas: recommendations of a European expert group.
abstract: With a prevalence of 2.6-4.5 %, infantile haemangiomas (IH) represent the most common tumour of infancy. While the majority of IH does not require therapy and regresses spontaneously, about 10 % of IH exhibit complications such as obstruction, ulceration or disfigurement. With the advent of oral propranolol, many conventional treatment options have become obsolete. This paper summarizes current recommendations for management of complicated IH. These recommendations have been written by an expert group after a consensus process including bibliographic review, several drafts of synthesis, meetings with quantitative voting system and redaction of an approved final manuscript.
  
  
  CONCLUSIONS
  Oral propranolol is the first-line agent for the treatment of complicated IH.
  
  
  BACKGROUND
  • Infantile haemangiomas (IH) are the most common tumours of infancy. Within a very short period after its discovery and long before the publication of randomized controlled trials, propranolol has become the number one agent for the treatment of complicated IH. What is New: • We report IH treatment recommendations of an international, interdisciplinary team of experts, based on an up-to-date review of the literature.
authors.affiliation: Department of Paediatrics and Paediatric Dermatology, Catholic Children's Hospital Wilhelmstift, Liliencronstr. 130, Hamburg, 22149, Germany, p.hoeger@KKH-Wilhelmstift.de.
authors.forename: Peter H
authors.initials: PH
authors.lastname: Hoeger
authors.forename: John I
authors.initials: JI
authors.lastname: Harper
authors.forename: Eulalia
authors.initials: E
authors.lastname: Baselga
authors.forename: Damien
authors.initials: D
authors.lastname: Bonnet
authors.forename: Laurence M
authors.initials: LM
authors.lastname: Boon
authors.forename: Marta
authors.initials: M
authors.lastname: Ciofi Degli Atti
authors.forename: Maya
authors.initials: M
authors.lastname: El Hachem
authors.forename: Arnold P
authors.initials: AP
authors.lastname: Oranje
authors.forename: Agneta Troilius
authors.initials: AT
authors.lastname: Rubin
authors.forename: Lisa
authors.initials: L
authors.lastname: Weibel
authors.forename: Christine
authors.initials: C
authors.lastname: Léauté-Labrèze
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001017:Aortic Coarctation / Q000150:complications; D017679:Cryotherapy; D003937:Diagnosis, Differential; D004954:Esthetics; D005124:Eye Abnormalities / Q000150:complications; D005938:Glucocorticoids / Q000627:therapeutic use; D006391:Hemangioma / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D053685:Laser Therapy; D020752:Neurocutaneous Syndromes / Q000150:complications; D010789:Phototherapy; D011433:Propranolol / Q000627:therapeutic use; D012307:Risk Factors; D020123:Sirolimus / Q000627:therapeutic use; D019043:Vascular Neoplasms / Q000175:diagnosis; D057832:Watchful Waiting
chemical_list: D000319:Adrenergic beta-Antagonists; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011433:Propranolol; D020123:Sirolimus